Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference
Although PD-L1 testing is standard in some cases, many patients end up on Keytruda without really benefiting,” said Faith Zaslavsky, CEO of Ignite Proteomics and IMAC Holdings. “Our analysis shows ...
Ignite Proteomics presents data on MHC-II as predictor of pembrolizumab response
Ignite Proteomics announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to ...
manilatimes5d
Jamf named as a Representative Vendor in the 2025 Gartner® Market Guide for Endpoint Management Tools
MINNEAPOLIS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Today, J amf (NASDAQ: JAMF) the standard in managing and securing Apple at work, announced it has been included as a Representative Vendor in the 2025 ...
Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay
Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), today announced the completed transfer of Proprietary Laboratory Analyses (PLA) code 0249U – originally issued to Theralink ...